Sponsors pursuing approval of new drugs that demonstrate central nervous system activity should expect to perform thorough assessments of any potential for abuse, and be aware of specific NDA requirements.
Source: Clinical Trials Advisor
Sponsors pursuing approval of new drugs that demonstrate central nervous system activity should expect to perform thorough assessments of any potential for abuse, and be aware of specific NDA requirements.
Source: Clinical Trials Advisor